Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Blood|August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaPhilippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.
Haematologica|April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patientsMarie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Blood Advances|June 3, 2026
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUSSonja Zweegman, Thierry Facon, Vania Hungria, et al.
Blood|October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
JAMA Oncology|August 12, 2018
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysisFrancesca Gay, Graham Jackson, Laura Rosiñol, et al.
Blood|March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease ResultsJill Corre, Laure Vincent, Philippe Moreau, et al.
Clinical Hematology International|June 1, 2026
Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in FranceDecaux Olivier, Ronan Garlantezec, Aurore Perrot, et al.
Nature Medicine|February 5, 2025
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trialSaad Z Usmani, Thierry Facon, Vania Hungria, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
Blood|January 9, 2007
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeHervé Avet-Loiseau, Michel Attal, Philippe Moreau, et al.
Pageof 15